
ZURA Stock Forecast & Price Target
ZURA Analyst Ratings
Bulls say
Zura Bio is deemed a strong investment opportunity for this analyst, as the clinical-stage biotechnology company specializes in developing medicines for autoimmune and inflammatory diseases with high unmet medical needs. While external funding may pose risks for the company, Zura Bio's focus on executing phase 3 trials for its three clinical-stage product candidates and its consideration of partnerships give confidence in its future success. Furthermore, with a strong management team led by Dr. Nistala, who has extensive experience in translational medicine and clinical trial design, and sufficient cash to fund operations through 2027, Zura Bio is well positioned to achieve its goals.
Bears say
Zura Bio is currently facing various risks, including clinical, intellectual property, and regulatory/commercial risks, which may limit their potential for revenue growth and stock price potential. While the company is conducting Phase 2 trials for their potential treatments, there is no guarantee of success and their financial results and fundraising efforts may not be enough to overcome these risks. The company also faces competition in the market and the founder's experience may not be enough to ensure success in this fast-paced industry.
This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.
ZURA Analyst Forecast & Price Prediction
Start investing in ZURA
Order type
Buy in
Order amount
Est. shares
0 shares